Biotech

Prometheus Biosciences, Inc.

1

Articles

Deal Party

Top Role

Apr 11, 2026

First Mention

Apr 11, 2026

Last Mention

1.55

Relevance Score

Coverage Timeline

April 2026

Keytruda’s $25B Question: Merck’s Playbook as Patent Expiry Nears Money Deal Party

Apr 11, 2026

The Prometheus (anti-TL1A) and Harpoon (T cell engager) acquisitions, $1.35 billion and $1.8 billion, respectively, signal Merck’s appetite for long-dated pipeline bets.